About the Company
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZGNX News
Did Hedge Funds Make The Right Call On Zogenix, Inc. (ZGNX)
With this in mind, let’s take a look at the recent hedge fund activity surrounding Zogenix, Inc. (NASDAQ:ZGNX) and determine whether hedge funds had an edge regarding this stock. Video ...
After epilepsy setback, Zogenix buys Modis and rare disease drug for $400m
Zogenix will also pay a 5% royalty on any future net sales of MT1621. Zogenix’s other drug candidate for a rare kind of childhood epilepsy is facing a delay after the FDA refused in April to ...
Domain Partners VI, L.P.'s Net Worth
Who is Domain Partners VI, L.P.? Domain Partners VI, L.P. has an estimated net worth of $86.7 Million. This is based on reported shares across multiple companies, which include ZOGENIX, INC ...
Kim P. Kamdar's Net Worth
Who is Kim P. Kamdar? Kim P. Kamdar has an estimated net worth of $2.25 Million. This is based on reported shares across multiple companies, which include MARINUS PHARMACEUTICALS INC, GLAUKOS Corp ...
Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does
Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
STIHL Inc.
This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...
Snap Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
P10, Inc. (PX) Stock Price, News, Quote & History - Yahoo Finance
P10 ( NYSE:PX ) Full Year 2023 Results Key Financial Results Revenue: US$241.7m (up 22% from FY 2022). Net loss... P10, Inc. (NYSE:PX) Q4 2023 Earnings Call Transcript February 29, 2024 P10, Inc ...
Snap Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...